An innovative clinical-stage gene therapy company with the goal of transforming the lives of patients suffering from severe degenerative diseases of the eye and central nervous system.
Based in Paris, France, GenSight Biologics (Paris: SIGHT) is a late clinical-stage biopharmaceutical company developing novel gene therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. In 2015, management engaged RooneyPartners to provide media relations support as the company prepared for an IPO to fund a crucial series of clinical trials, ultimately choosing to list on the Euronext Paris exchange.
Building on our successful PR partnership, GenSight added social and digital strategy to the brief in 2016, following the completion of a social media audit and digital opportunity analysis conducted by RooneyPartners’ digital and content strategy team.
Our media relations campaign on behalf of GenSight has generated numerous stories, including high-value outcomes across top-tier business media and influential trade outlets. These pieces have focused on a variety of key storylines, positioning GenSight and its management team as industry authorities on ophthalmologic conditions and visionary leaders in the world of gene therapy and optogenetics.
The digital and social media strategy for GenSight has leveraged traditional media outcomes, relevant disease awareness days, KOL events, and other company milestones to build digital reach and engagement within the biotech, investor and ophthalmology communities.
More recently, RooneyPartners has consulted with GenSight on the development of a digital, social media and content strategy to support the potential commercialization of GS010, the company’s lead therapy to treat Leber Hereditary Optic Neuropathy (LHON), a rare maternally inherited genetic disease that causes irreversible and severe vision loss, eventually leading to blindness.